logo

Heron Therapeutics Inc. (HRTX)



Trade HRTX now with
  Date
  Headline
8/9/2021 8:09:14 AM Heron Therapeutics Q2 Loss/shr Widens To $0.62 From $0.61 Prior Year
7/6/2021 8:36:40 AM Heron Therapeutics Reports 340B Prime Vendor Contract With Apexus For ZYNRELEF
7/1/2021 8:33:49 AM Heron Announces U.S. Launch And Availability Of ZYNRELEF For Management Of Postoperative Pain For Up To 72 Hours
5/25/2021 9:03:18 AM Heron Therapeutics Reports Sale Of $150 Mln Of Senior Unsecured Convertible Promissory Notes In Private Placement
2/24/2021 8:36:16 AM Heron Therapeutics Q4 Net Loss $62.3 Mln Or $0.68/shr Vs. Loss $57.9 Mln Or $0.65/shr Prior Year
1/21/2021 8:41:20 AM Heron Publishes Results From EPOCH 1 Follow-On Study Of HTX-011 In Patients Undergoing Bunionectomy Surgery
1/11/2021 8:44:31 AM Heron Annouunces Progress In Pain Management And CINV Franchises
11/13/2020 8:33:24 AM Heron Therapeutics Resubmits NDA To FDA For HTX-011 For Treatment Of Postoperative Pain
11/5/2020 8:44:14 AM Heron Therapeutics Q3 Loss/Shr $0.64 Vs Loss $0.42 Last Year
9/28/2020 8:36:19 AM Heron Therapeutics Receives EU Authorization For ZYNRELEF For Postoperative Pain
9/16/2020 8:35:58 AM Heron Therapeutics Announces Publication Of Results From EPOCH 2 Follow-On Study